RAIN · Insider Trading
Rain Enhancement Technologies Holdco, Inc. Class A Common Stock
Every open-market purchase and sale reported by RAIN officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-21 | Randy Seidl | Chief Executive Officer | Buy | +110,000 | +$104.22K |
| 2026-08-20 | Randy Seidl | Chief Executive Officer | Buy | +110,000 | +$104.22K |
| 2026-08-12 | Randy Seidl | Chief Executive Officer | Buy | +42,514 | +$100.95K |
| 2024-01-29 | BVF II GP LLC | Director | U | −85,768,030 | — |
| 2024-01-26 | Stefani Wolff | Director | D | −79,000 deriv. | — |
| 2024-01-26 | Tran Nguyen | Director | D | −111,486 deriv. | — |
| 2024-01-26 | Aaron I. Davis | Director | U | −79,726 | — |
| 2024-01-26 | Erik Atkisson | General Counsel and CCO | D | −180,251 deriv. | — |
| 2024-01-26 | Franklin M Berger | Director | U | −1,005,207 | — |
| 2024-01-26 | Peter Radovich | Director | U | −8,796 | — |
| 2024-01-26 | Robert Doebele | See Remarks | U | −476,827 | — |
| 2024-01-26 | Avanish Vellanki | Chairman and CEO | U | −2,550,910 | — |
| 2024-01-26 | Gorjan Hrustanovic | Director | D | −55,000 deriv. | — |
| 2023-12-18 | TANG CAPITAL PARTNERS LP | 10%+ Owner | Sell | −521,919 | −$628.24K |
| 2023-10-13 | TANG CAPITAL PARTNERS LP | 10%+ Owner | Buy | +852,435 | +$837.09K |
| 2023-08-11 | Josephine Bruce | Principal Fin. & Acc. Officer | A | +10,800 deriv. | — |
| 2023-08-11 | Aaron I. Davis | Director | A | +35,000 deriv. | — |
| 2023-08-11 | Franklin M Berger | Director | A | +35,000 deriv. | — |
| 2023-08-11 | Stefani Wolff | Director | A | +35,000 deriv. | — |
| 2023-08-11 | Erik Atkisson | General Counsel and CCO | A | +60,251 deriv. | — |
| 2023-08-11 | Gorjan Hrustanovic | Director | A | +35,000 deriv. | — |
| 2023-08-11 | Robert Doebele | See Remarks | A | +149,100 deriv. | — |
| 2023-08-11 | Peter Radovich | Director | A | +35,000 deriv. | — |
| 2023-08-11 | Avanish Vellanki | Chairman and CEO | A | +399,750 deriv. | — |
| 2023-08-11 | Tran Nguyen | Director | A | +35,000 deriv. | — |
| 2023-06-01 | TANG CAPITAL PARTNERS LP | 10%+ Owner | Buy | +3,264,819 | +$3.48M |
| 2023-05-24 | Boxer Capital, LLC | — | Sell | −3,980,000 | −$4.97M |
| 2023-03-03 | Erik Atkisson | General Counsel and CCO | A | +120,000 deriv. | — |
| 2023-02-17 | Robert Doebele | See Remarks | A | +123,325 deriv. | — |
| 2023-02-17 | Avanish Vellanki | Chairman and CEO | A | +318,600 deriv. | — |
| 2023-02-17 | Richard Paul Bryce | Chief Medical Officer | A | +110,000 deriv. | — |
| 2023-02-17 | Nelson Cabatuan | VP of Finance & Admin | A | +65,325 deriv. | — |
| 2022-11-23 | Franklin M Berger | Director | Buy | +122,000 | +$987.79K |
| 2022-11-14 | Franklin M Berger | Director | Buy | +42,881 | +$250.00K |
| 2022-11-10 | BVF I GP LLC | Director | Buy | +17,103,580 | +$99.71M |
| 2022-11-08 | Aaron I. Davis | Director | Buy | +972,212 | +$5.67M |
| 2022-08-19 | Franklin M Berger | Director | A | +20,000 deriv. | — |
| 2022-08-19 | Aaron I. Davis | Director | A | +20,000 deriv. | — |
| 2022-08-19 | Peter Radovich | Director | A | +20,000 deriv. | — |
| 2022-08-19 | Tran Nguyen | Director | A | +20,000 deriv. | — |
| 2022-08-19 | Stefani Wolff | Director | A | +20,000 deriv. | — |
| 2022-08-19 | Gorjan Hrustanovic | Director | A | +20,000 deriv. | — |
| 2022-07-07 | Robert Doebele | See Remarks | M | +3,890 | +$15.37K |
| 2022-06-02 | Avanish Vellanki | Chairman and CEO | Buy | +25,000 | +$57.25K |
| 2022-04-15 | Robert Doebele | See Remarks | M | +3,000 | +$11.85K |
| 2022-04-15 | Avanish Vellanki | Chairman and CEO | G | — | — |
| 2022-04-04 | Robert Doebele | See Remarks | M | +2,000 | +$7.90K |
| 2022-03-15 | Avanish Vellanki | President and CEO | M | +14,468 | +$57.87K |
| 2022-02-04 | Richard Paul Bryce | Chief Medical Officer | A | +53,064 deriv. | — |
| 2022-02-04 | Robert Doebele | EVP, Chief Scientific Officer | A | +72,000 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Randy Seidl | Chief Executive Officer | 754,834 | $477.51K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the RAIN quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.